Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 30;20(3):593.
doi: 10.3390/ijms20030593.

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

Affiliations
Review

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

Beatriz Ballester et al. Int J Mol Sci. .

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2⁻4 years after diagnosis. A significant number of IPF patients have risk factors, such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer (LC) (mostly non-small cell lung cancer (NSCLC)). In fact, IPF itself increases the risk of LC development by 7% to 20%. In this regard, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with LC, such as myofibroblast/mesenchymal transition, myofibroblast activation and uncontrolled proliferation, endoplasmic reticulum stress, alterations of growth factors expression, oxidative stress, and large genetic and epigenetic variations that can predispose the patient to develop IPF and LC. The current approved IPF therapies, pirfenidone and nintedanib, are also active in LC. In fact, nintedanib is approved as a second line treatment in NSCLC, and pirfenidone has shown anti-neoplastic effects in preclinical studies. In this review, we focus on the current knowledge on the mechanisms implicated in the development of LC in patients with IPF as well as in current IPF and LC-IPF candidate therapies based on novel molecular advances.

Keywords: idiopathic pulmonary fibrosis (IPF); lung cancer (LC); non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Cell types and cellular processes involved in lung cancer (LC) and idiopathic pulmonary fibrosis (IPF). Lung resident fibroblasts, pericytes, pleural mesothelial cells (PMC), circulating fibrocytes, vascular endothelial cells, and epithelial cells (Alveolar type II cells (ATII) in IPF and cancer epithelial cells in LC) are transformed to IPF myofibroblast or mesenchymal phenotype and cancer-associated fibroblasts (CAFs). Myofibroblasts and cancer cells are characterized by altered cell-cell communication, migration properties, and tissue invasion through basement membranes and the extracellular matrix. IPF myofibroblasts and ATII cells acquire senescent identities, but the presence of this phenotype is controversial in LC. Otherwise, endoplasmic reticulum (ER) stress is induced in IPF, while autophagy is defective in IPF. However, the function of both processes is controversial in LC. Finally, apoptosis is induced in ATII cells, but IPF myofibroblasts and cancer cells evade apoptosis.

References

    1. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.F., Flaherty K.R., Lasky J.A., et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL. - DOI - PMC - PubMed
    1. Ley B., Collard H.R., King T.E., Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011;183:431–440. doi: 10.1164/rccm.201006-0894CI. - DOI - PubMed
    1. Meyer E.C., Liebow A.A. Relationship of Interstitial Pneumonia Honeycombing and Atypical Epithelial Proliferation to Cancer of the Lung. Cancer. 1965;18:322–351. doi: 10.1002/1097-0142(196503)18:3<322::AID-CNCR2820180310>3.0.CO;2-J. - DOI - PubMed
    1. Karampitsakos T., Tzilas V., Tringidou R., Steiropoulos P., Aidinis V., Papiris S.A., Bouros D., Tzouvelekis A. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2017;45:1–10. doi: 10.1016/j.pupt.2017.03.016. - DOI - PubMed
    1. Hubbard R., Venn A., Lewis S., Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 2000;161:5–8. doi: 10.1164/ajrccm.161.1.9906062. - DOI - PubMed

MeSH terms